The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?

Marco Matucci-Cerinic1*, Mirko Manetti1,2, Cosimo Bruni1, Ines Chora3, Silvia Bellando-Randone1, Gemma Leprī1, Amato De Paulis4 and Serena Guiducci1

Abstract
Systemic sclerosis is considered a disease dominated by a “loss of angiogenesis”, although in its early phases evidence indicates a disturbed angiogenic response only. In fact, microvascular changes are primarily due to endothelial cell injury, triggering downstream significant enlargement of the capillary in an inflammatory environment, followed by capillary rupture (microhemorrhages). Subsequent pro-angiogenic efforts lead to an aberrant angiogenesis and, eventually, to a total loss of vessel repair and regeneration (loss of angiogenesis). This clearly suggests that the pathogenetic process has a steady progression: from an early excessive pro-angiogenesis, to an aberrant microvascular regeneration, then ending with a late loss of angiogenesis. Herein, we suggest the loss of angiogenesis should not be considered as an overall “myth” characterizing systemic sclerosis but as a very late event of the vascular pathogenesis. Future research should be oriented essentially on the earlier phases dominated by excessive pro-angiogenesis and microvascular aberration.

Keywords: Scleroderma, Systemic sclerosis, Angiogenesis

Background
In systemic sclerosis (SSc), the loss of angiogenesis has been considered a pivotal event characterizing the disease from its onset. In reality, several pathways of endothelial cell (EC) dysfunction and defective angiogenesis have been identified (Table 1) [1–10]. Paradoxically, in SSc significant concentrations of intrinsic pro-angiogenic factors have been found in the vasculature or adjacent tissues [1, 2, 11]. This evidence is apparently in contrast with the main hypothesis that SSc is fundamentally and originially characterized by a lack or loss of angiogenesis. In fact, the eventual inability to regenerate injured vessels may be due to the failure of some angiogenic steps, such as lumen formation or vessel maturation or stabilization. Clearly, the persistent endothelial injury may not only switch on but also significantly perpetuate this process [2]. Whether dysregulated levels of circulating angiogenic or angiostatic factors (or both) are a cause or a consequence of an ongoing vascular disease is still unknown [2].

In early SSc pathogenesis, inflammatory cells have a significant role. In fact, in the edematous tissues, where fibrosis is still absent but inflammation dominates, a significant number of immune cells surround the microvessels. The role of these cells is pivotal in triggering the activation of cells present in the tissues, in particular myofibroblasts, through the release of TGFβ and other cytokines and growth factors [12]. However, other questions remain unanswered. The first is if autoantibodies are pathogenic, contributing to endothelial damage and thus an expression of disease activity, or just innocent bystanders. The second is if endothelial circulating progenitors as well as the resident mesenchymal cells and the cells surrounding the vessel (pericytes, telocytes) may participate in the endothelial dys-function and the loss of angiogenesis and foster the endothelial to mesenchymal transition (endoMT) process [4, 10, 13].
Table 1 Evidence for endothelial cell dysfunction and defective angiogenic pathways in systemic sclerosis

| Activity | Early | Active | Late |
|----------|-------|--------|------|
| Nailfold Videocapillaroscopic modifications | Hyper-angiogenesis | Giant capillaries | Desert areas |
| Raynaud’s phenomenon | Loss of angiogenesis | Capillaries |
| Clinical features | Raynaud’s phenomenon | Raynaud’s phenomenon |

Angiogenesis is a complex and finely balanced physiological process, consisting of the formation of new vessels from pre-existing ones, mainly triggered by damage or tissue hypoxia [1]. Sprouting angiogenesis encompasses an increase in vasopermeability, leading to plasma and protein extravasation, which works as a temporary scaffold for migrating ECs. Matrix metalloproteinases, secreted by the endothelium, break down the vascular basement membrane and allow the invasion of the surrounding stroma by ECs, directed towards the pro-angiogenic stimulus [1]. This process is paralleled by proliferation and organization of newly formed ECs into three-dimensional tubular structures. Lumen formation and vessel wall stabilization by pericytes are the final phases of sprouting angiogenesis and lead to the creation of a functional network of new capillary vessels [1]. Physiological angiogenesis is finely balanced and regulated by stimulating (pro-angiogenic) and inhibiting (anti-angiogenic) factors [1, 2]. Vascular endothelial growth factor (VEGF) has a key role in controlling several cellular and molecular steps in the angiogenic cascade [1]. Indeed, it stimulates ECs to increase their migration and to initiate the proliferative process until a complete tubular structure is formed [1]. Although the majority of studies in the literature highlight the loss of angiogenesis in SSc, in practice this condition is present only in the late phase of SSc evolution (Fig. 1). In fact, in the early stage of the disease a vasculopathy with a pro-inflammatory state is evident and an increased production of pro-angiogenic factors (e.g., VEGF, endothelin-1) has been shown [14, 15], despite the defective response of ECs to these stimuli [16]. Moreover, intrinsic abnormal properties of the cellular components of the blood vessels, the presence of fibroblast-derived anti-angiogenic factors, dysfunctional circulating endothelial progenitor cells, and an abnormal expression of transcription factors, including Fra2 and Flt1, may further contribute to SSc vasculopathy [17, 18].

Vascular abnormalities are indeed manifest very early in SSc [3, 19] and are characterized by a progressive involvement of the vessel wall. The main vascular modifications observed with electron and optical microscopy are EC activation/injury and apoptosis, opening of the EC tight junctions allowing inflammatory cell migration, basal membrane duplication, and intimal thickening with vessel narrowing and obliteration [3].

In the early phase, nailfold videocapillaroscopy shows clusters of giant capillaries and tissue edema surrounded by normal capillaries of different shapes. Micro-hemorrhages, derived from the break of megacapillaries pushed to their upper limits by an excessive and uncontrolled angiogenesis, embedded in an inflammatory environment, are clearly detectable [3]. This “push” of angiogenesis and the modification of the capillary shape may depend upon the persistent high circulating levels and tissue over-expression of VEGF [11, 14]. These early vascular changes subsequently lead to vascular tone dysfunction, followed by reduced capillary blood flow, with consequent chronic tissue hypoxia, further exacerbated by extracellular matrix accumulation and fibrosis [3]. The process is then characterized by a profoundly disturbed and aberrant angiogenesis (tortuous, ramified, and tree-like capillaries; Fig. 1). This phase is followed by a subsequent microvascular loss—known as loss of angiogenesis—which is due to defects in both vascular repair and growth of new vessels through vasculogenesis and angiogenesis [1], characterized by a capillaroscopic progressive reduction in capillary density, with large avascular areas (desertification) (Fig. 1).
This evidence demonstrates the switch from an initial pro- to a final anti-angiogenic environment linked to the preponderant action of angiostatic factors (e.g., VEGF165b, angiopoietin-2), resulting in the loss of new normal vessel formation and capillaries. In the early phase, the hypothesis that increased plasma levels of antiangiogenic VEGF165b isoforms profoundly disturb the pro-angiogenic effect of VEGF, being associated with the severity of capillary architectural derangement and loss, has found significant support [14]. The hypothesis that the initial excessive up-regulation of pro-angiogenic factors might lead to an even greater up-regulation of angiostatic factors is also interesting [2]. The reduction of capillary density consequently leads to an impairment in the supply of oxygen and nutrients and thus to a hypoxic state. In this situation, angiogenesis is usually triggered but in SSC the vascular recovery is profoundly disturbed and then impaired and the loss of angiogenesis with avascular areas becomes eventually a prominent event [20–22].

In clinics, SSC is characterized by an evolution which is frequently unpredictable, with abrupt acceleration and periods of quiescence. Therefore, awareness of the condition of the microvasculature in the frame of the disease evolution is crucial and may influence the clinical strategy according to a correct evaluation of the disease phase. In practice, it becomes of paramount importance to establish the real disease phase, which should not be centered on the mere measurement of the years from diagnosis but clearly aimed at understanding the “real time” of advancement of the microvascular disease (Fig. 1). In SSC, the evolution of microcirculatory modifications and the time to loss of angiogenesis may be very fast in diffuse SSC, while it is significantly slower in limited SSC. A switch of research interest to on the early phase of the disease might change the approach to the clinical setting in SSC. In this perspective, the choice of a vasoactive therapeutic strategy aiming at the modulation, in the “time” frame of each phase of microvascular involvement, of the angiogenic process might be a pivotal event changing the approach to SSC therapy in diffuse or limited SSC. In the future, targeting the early inflammatory pro-angiogenic process [22] leading to capillary aberration might be a relevant step to block the disease evolution to prevent the loss of angiogenesis.

**Conclusions**

The fate of SSC is dictated by the phase of evolution of the microvascular modifications observed in the patient [3]. It is clear that the capacity to define the real advancement of the microvascular involvement during SSC evolution, either in the diffuse or in the limited subset, will be significant for the choice of treatment (immunosuppressive, vasodilatory, vasoactive and its combination, future targeted therapies) to eventually achieve disease remission.

**Abbreviations**
EC: Endothelial cell; SSC: Systemic sclerosis; VEGF: Vascular endothelial growth factor

**Acknowledgements**
IC acknowledges the Foundation for the Development of Internal Medicine in Europe for its Research Grant.

**Funding**
Not applicable.

**Availability of data and materials**
Not applicable.

**Authors’ contributions**
MMC, MM, CB, IC, SBR, ADP, and SG conceived the paper and participated in drafting the manuscript. All authors read and approved the final manuscript.

**Competing interests**
The authors declare they have no competing interests.

**Consent for publication**
Not applicable.

**Ethics approval and consent to participate**
Not applicable.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1Department of Experimental and Clinical Medicine, Division of Rheumatology and Scleroderma Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Viale Pieraccini 18, 50139 Florence, Italy. 2Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, 50134 Florence, Italy. 3Department of Internal Medicine, São João Hospital Center, Al Prof Hernâni Monteiro, 4220-319 Porto, Portugal. 4Department of Translational Medical Sciences, Centro for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Corso Umberto I, 40, 80138 Naples, Italy.

**Published online:** 06 July 2017

**References**
1. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14:1241–54.
2. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep. 2012;14:56–63.
3. Matucci-Cerinic M, Kahaleh B, Wigley FM. Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953–62.
4. Manetti M, Guiducci S, Matucci-Cerinic M. The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem? Arthritis Res Ther. 2016;18:36.
5. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ieda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364:603–10.
6. Patashn S, Tampe D, Müller C, Setz C, Heinrich C, et al. Early endothelial progenitor cells (eEPGs) in systemic sclerosis (SSc)—dynamics of cellular regeneration and mesenchymal transdifferentiation. BMC Musculoskelet Disord. 2016;17:339.
7. Yamaguchi Y, Kuwana M. Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. Histol Histopathol. 2013;28:75–83.
8. Hirigoyen D, Burgos PI, Mezzano V, Duran J, Baniertos M, Saez CG, et al. Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther. 2015;17:332.
9. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008;3(1):e1452.
10. Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, De Paulis A, et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017;76(5):924–34.

11. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95:109–16.

12. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010;6:453–60.

13. Neveskaya T, Bykovskaya S, Lyssuk E, Shakhov I, Zapsjagaeva M, Mach E, et al. Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol. 2008;26(3):421–9.

14. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4:R11.

15. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999;26:74–84.

16. Tsou PS, Rabquer BJ, Ohara RA, Stinson WA, Campbell PL, et al. Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheumatology. 2016;55:745–54.

17. Toyama T, Asano Y, Miyagawa T, Nakamura K, Hrablyash M, Yamashita T, et al. The impact of transcriptional factor Fli1 deficiency on the regulation of angiogenesis. Exp Dermatol. 2017. doi:10.1111/exd.13341. [Epub ahead of print]

18. Takahashi T, Asano Y, Sugawara K, Yamashita T, Nakamura K, Saigusa R, et al. Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. J Exp Med. 2017;214:1129–51.

19. Brun C, Guiducci S, Bellando-Randone S, Lepri G, Braichi F, Fiori G, et al. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford). 2015;54:72–6.

20. Matucci-Cerinic M, Guiducci S, Romano E, Bellando-Randone S, Lepri G, Brun C, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis. 2013;72:423–7.

21. Koca SS, Ozgen M, Dagli AF, Gozel N, Ozercan IH, Isik A. The protective effects of bevacizumab in bleomycin-induced experimental scleroderma. Adv Clin Exp Med. 2016;25:249–53.